Fenebrutinib met primary goals in two late-stage trials for the treatment of two different forms of multiple sclerosis.
Roche Holding AG said a multiple sclerosis drug showed it could work for most forms of the disease in two late-stage trials, ...
When your body's immune cells attack you instead of protecting you, today's treatments tamp down the friendly fire but they ...
Roche's experimental multiple sclerosis drug achieved its main goal in one of two key late-stage trials testing it against ...
Zydus Lifesciences received USFDA approval for its Diroximel Fumarate capsules for multiple sclerosis, while concluding a ...
The damage can lead to both sudden “flares” of inflammation and a slow worsening of symptoms over time. Historically, MS has been broken down into specific subtypes, as detailed below. But the reality ...
The Swiss drugmaker reported that its Phase III trial known as FENhance 2 met its main goal in patients with relapsing multiple sclerosis. Fenebrutinib, taken twice daily, significantly reduced the ...
Two Phase 3 trials testing the investigational oral therapy fenebrutinib in people with multiple sclerosis (MS) have hit ...
Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...
FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday that a late-stage trial testing its multiple sclerosis drug ...
Roche (RHHBY) stock gains and TG Therapeutics (TGTX) stock falls as the Swiss firm's new drug for multiple sclerosis succeeds in two late-stage trials. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback